Mixed connective tissue disease: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: {{seealso|Scleroderma}} Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap between systemic lupus erythematosus, scler...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{seealso|Scleroderma}} | {{seealso|Scleroderma}} | ||
Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap between systemic lupus erythematosus, scleroderma, and polymyositis; a specific | Now understood to be a distinct disease, '''mixed connective tissue disease (MCTD)''' is variously considered an overlap (i.e., '''overlap connective tissue disease''') between [[systemic lupus erythematosus]] (SLE), [[scleroderma]], and [[polymyositis]]; a specific subset of [[scleroderma]] with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity. | ||
Most patients with MCTD have [[autoantibody|autoantibodies]] | Most patients with MCTD have [[autoantibody|autoantibodies]] characteristic of scleroderma, such as [[U1 small nuclear ribonucleoprotein]]s (anti-U1 snRNP OR anti-U1 RNP), and have clinical [[Raynaud's phenomenon]]. | ||
Revision as of 06:51, 31 July 2010
- See also: Scleroderma
Now understood to be a distinct disease, mixed connective tissue disease (MCTD) is variously considered an overlap (i.e., overlap connective tissue disease) between systemic lupus erythematosus (SLE), scleroderma, and polymyositis; a specific subset of scleroderma with objective features of other diseases, such as SLE or polymyositis; or a distinct disease entity.
Most patients with MCTD have autoantibodies characteristic of scleroderma, such as U1 small nuclear ribonucleoproteins (anti-U1 snRNP OR anti-U1 RNP), and have clinical Raynaud's phenomenon.